Company record · ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc.'s interim chief financial officer on the record is Kevin G. Sarney, effective June 26, 2026, per the filing record.
The record holds 1 verified CFO change for Atara Biotherapeutics, Inc. from Form 8-K filings, filed June 26, 2026 and the CFO signature on its 10-K filed March 16, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled (interim) |
|---|---|
| Officer | Kevin G. Sarney |
| Title as printed | interim chief financial officer |
| Basis | Latest move: interim, 8-K filed June 26, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-06-26Interim
Atara Biotherapeutics, Inc. names Kevin G. Sarney interim CFOeffective June 26, 2026 · 8-K filed June 26, 2026 · sec.gov, Item 5.02
2026-03-1610-K signature
Yanina Grant-Huerta signed the annual report as Chief Accounting Officer ( Principal Financial and Accounting Officer )
10-K filed March 16, 2026 · sec.gov
“/s/ Yanina Grant-Huerta Yanina Grant-Huerta Chief Accounting Officer ( Principal Financial and Accounting Officer )”
Company
| Ticker | ATRA |
|---|---|
| SEC CIK | 0001604464 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
| Roster note | The DEF 14A filed 2026-04-24 does not name Yanina Grant-Huerta near a Chief Financial Officer title; check for a change. An 8-K with Item 5.02 was filed on 2026-06-26, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Allogene Therapeutics, Inc.ALLO
Departure disclosed · Geoffrey Parker · no successor on the record yet
Armata Pharmaceuticals, Inc.ARMP
CFO: David House · effective July 17, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
ImageneBio, Inc.IMA
CFO: Yanina Grant-Huerta · effective July 20, 2026
IRulya Therapeutics Inc.QNCX
CFO: John Militello · effective not stated in the source
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Kalaris Therapeutics, Inc.KLRS
CFO: Liisa Bayko · effective July 20, 2026
Precision BioSciences, Inc.DTIL
CFO: Naresh Tanna · effective August 1, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.